Evolving role of topotecan in treating small-cell lung cancer

Clinical Lung Cancer

Volumn 5, Issue 5, 2004, Pages 270-272

  Reddy, G Kesava ^a   Belani, Chandra P ^a   Jain, Vinay K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; HEMOPOIETIC GROWTH FACTOR; PACLITAXEL; TOPOTECAN;

ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL STUDY; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TOLERABILITY; HUMAN; LUNG SMALL CELL CANCER; MONOTHERAPY; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 2442528957     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-7304(11)70348-5     Document Type: Article

References (9)

1. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17:658-667.
2. Perez-Soler R, Glisson BS, Lee JS, et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 1996; 14:2785-2790.
3. Huber RM, Gatzemeier U, von Pawel J, et al. Topotecan in second-line treatment of small cell lung cancer - reduced toxicity with individualized therapy. Proc Am Soc Clin Oncol 2000; 19:546a (Abstract #2153).
4. Takeda K, Negoro S, Sawa T, et al. A phase II study of topotecan in patients with relapsed small-cell lung cancer. Clin Lung Cancer 2003; 4:224-228.
5. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997; 15:2090-2096.
6. Schiller JH, Kim K, Hutson P, et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 1996; 14:2345-2352.
7. Eckardt JR, Von Pawel J, Hainsworth JD, et al. Single agent oral topotecan (oral) versus intravenous topotecan (I.V.) in patients (pts) with chemosensitive small cell lung cancer (SCLC): an international phase III study. Proc Am Soc Clin Oncol 2003; 22:619 (Abstract #2488).
8. Greco FA. Topotecan as first-line therapy for small cell lung cancer. Lung Cancer 2003; 41(suppl 4):S9-S16.
9. Frasci G, Nicolella G, Comella P, et al. A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study. Br J Cancer 2001; 84:1166-1171.